MicroRNA-7 inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of rapamycin pathway suppression

Qin,Ancheng; Qian,Weifeng

doi:10.3892/ijmm.2018.3864

MicroRNA-7 inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of rapamycin pathway suppression

Authors:
- Ancheng Qin
- Weifeng Qian
View Affiliations

Affiliations: Department of General Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu 215002, P.R. China
Published online on: September 7, 2018 https://doi.org/10.3892/ijmm.2018.3864
Pages: 2503-2514
Copyright: © Qin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA‑7 (miR‑7) is a non‑coding RNA that inhibits colorectal cancer (CRC) cell proliferation, migration and invasion. miR‑7 effectively silences TYRO3 expression, and the close association between TYRO3 and CRC has previously been reported. Therefore, the present study aimed to assess the roles and molecular mechanisms of TYRO3 and miR‑7 in the development of CRC. The expression levels of miR‑7 and TYRO3 in CRC tissues and cell lines were detected by reverse transcription‑quantitative polymerase chain reaction. A dual‑luciferase reporter assay was also performed to confirm whether TYRO3 was a target of miR‑7. The effect of miR‑7 and TYRO3 on cell proliferation, migration and invasion was detected in vitro with MTT, wound healing and cell invasion assays, respectively. The expression of proteins associated with the phosphoinositide 3‑kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway was detected by western blot analysis. The results indicated that the expression of miR‑7 was downregulated and the levels of TYRO3 were gradually increased in CRC tissues and cell lines. TYRO3 was identified as a functional target of miR‑7, and its expression was negatively regulated by miR‑7 in CRC cell lines. The functional studies demonstrated that miR‑7 knockdown promoted the proliferation, migration and invasion of CRC cells, while knockdown of TYRO3 repressed these biological processes. In addition, pathway analyses revealed that the oncogenic effect of TYRO3 was associated with PI3K/AKT/mTOR pathway inhibition. In conclusion, the data suggested that miR‑7 promoted the development of CRC by targeting oncogenic TYRO3, which may be mediated by inhibition of the PI3K/AKT/mTOR signaling pathway. Thus, miR‑7 may serve as an independent prognostic biomarker in patients with CRC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
3	Van Cutsem E, Cervantes A and Nordlinger B: Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25(Suppl 3): iii1–iii9. 2014. View Article : Google Scholar : PubMed/NCBI
4	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6	Petri A, Lindow M and Kauppinen S: MicroRNA silencing in primates: Towards development of novel therapeutics. Cancer Res. 69:393–395. 2009. View Article : Google Scholar : PubMed/NCBI
7	Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, et al: MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 16:430–441. 2010. View Article : Google Scholar : PubMed/NCBI
8	Loo JM, Scherl A, Nguyen A, Man FY, Weinberg E, Zeng Z, Saltz L, Paty PB and Tavazoie SF: Extracellular metabolic energetics can promote cancer progression. Cell. 160:393–406. 2015. View Article : Google Scholar : PubMed/NCBI
9	Chen WQ, Hu L, Chen GX and Deng HX: Role of microRNA-7 in digestive system malignancy. World J Gastrointest Oncol. 8:121–127. 2016. View Article : Google Scholar : PubMed/NCBI
10	Suto T, Yokobori T, Yajima R, Morita H, Fujii T, Yamaguchi S, Altan B, Tsutsumi S, Asao T and Kuwano H: MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis. 36:338–345. 2015. View Article : Google Scholar
11	Li Y, Li Y, Liu Y, Xie P, Li F and Li G: PAX6, a novel target of microRNA-7, promotes cellular proliferation and invasion in human colorectal cancer cells. Dig Dis Sci. 59:598–606. 2014. View Article : Google Scholar
12	Ohashi K, Mizuno K, Kuma K, Miyata T and Nakamura T: Cloning of the cDNA for a novel receptor tyrosine kinase, Sky, predominantly expressed in brain. Oncogene. 9:699–705. 1994.PubMed/NCBI
13	Schmitz R, Valls AF, Yerbes R, von Richter S, Kahlert C, Loges S, Weitz J, Schneider M, Ruiz de Almodovar C, Ulrich A and Schmidt T: TAM receptors Tyro3 and Mer as novel targets in colorectal cancer. Oncotarget. 7:56355–56370. 2016. View Article : Google Scholar : PubMed/NCBI
14	Vouri M and Hafizi S: TAM receptor tyrosine kinases in cancer drug resistance. Cancer Res. 77:2775–2778. 2017. View Article : Google Scholar
15	Martinelli E, Martini G, Cardone C, Troiani T, Liguori G, Vitagliano D, Napolitano S, Morgillo F, Rinaldi B, Melillo RM, et al: AXL is an oncotarget in human colorectal cancer. Oncotarget. 6:23281–23296. 2015. View Article : Google Scholar : PubMed/NCBI
16	Kabir TD, Ganda C, Brown RM, Beveridge DJ, Richardson KL, Chaturvedi V, Candy P, Epis M, Wintle L, Kalinowski F, et al: A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Hepatology. 67:216–231. 2018. View Article : Google Scholar
17	Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
18	Chaturvedi MM, Sung B, Yadav VR, Kannappan R and Aggarwal BB: NF-κB addiction and its role in cancer: 'One size does not fit all'. Oncogene. 30:1615–1630. 2011. View Article : Google Scholar
19	Thorson AG, Christensen MA and Davis SJ: The role of colonoscopy in the assessment of patients with colorectal cancer. Dis Colon Rectum. 29:306–311. 1986. View Article : Google Scholar : PubMed/NCBI
20	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
21	Nagano Y, Toiyama Y, Okugawa Y, Imaoka H, Fujikawa H, Yasuda H, Yoshiyama S, Hiro J, Kobayashi M, Ohi M, et al: MicroRNA-7 is associated with malignant potential and poor prognosis in human colorectal cancer. Anticancer Res. 36:6521–6526. 2016. View Article : Google Scholar : PubMed/NCBI
22	Xu K, Chen Z, Qin C and Song X: miR-7 inhibits colorectal cancer cell proliferation and induces apoptosis by targeting XRCC2. Onco Targets Ther. 7:325–332. 2014. View Article : Google Scholar : PubMed/NCBI
23	Xiong S, Zheng Y, Jiang P, Liu R, Liu X and Chu Y: MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci. 7:805–814. 2011. View Article : Google Scholar : PubMed/NCBI
24	Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, Jiang L, Zhang Y and Dou J: MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT 3 pathway. Stem Cells. 32:2858–2868. 2014. View Article : Google Scholar : PubMed/NCBI
25	Zhang N, Li X, Wu CW, Dong Y, Cai M, Mok MT, Wang H, Chen J, Ng SS, Chen M, et al: microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene. 32:5078–5088. 2013. View Article : Google Scholar
26	Chien CW, Hou PC, Wu HC, Chang YL, Lin SC, Lin SC, Lin BW, Lee JC, Chang YJ, Sun HS and Tsai SJ: Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer. Oncogene. 35:5872–5881. 2016. View Article : Google Scholar : PubMed/NCBI
27	Zhu S, Wurdak H, Wang Y, Galkin A, Tao H, Li J, Lyssiotis CA, Yan F, Tu BP, Miraglia L, et al: A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci USA. 106:17025–17030. 2009. View Article : Google Scholar : PubMed/NCBI
28	Gustafsson A, Boström AK, Ljungberg B, Axelson H and Dahlback B: Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma. PLoS One. 4:e75752009. View Article : Google Scholar : PubMed/NCBI
29	Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, Sugarbaker DJ and Fletcher JA: AXL regulates mesothelioma proliferation and invasiveness. Oncogene. 30:1643–1652. 2011. View Article : Google Scholar
30	Zhong Z, Wang Y, Guo H, Sagare A, Fernández JA, Bell RD, Barrett TM, Griffin JH, Freeman RS and Zlokovic BV: Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone- binding globulin-like region. J Neuroscience. 30:15521–15534. 2010. View Article : Google Scholar